Keytruda / K药

Keytruda / K药 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as [[Merck|默沙东]]’s PD-1 blockbuster and the main comparator for the episode’s [[PD1MarketSaturation|PD-1 market saturation]] and [[PD1VEGFBispecific|PD-1/VEGF bispecific]] discussion. The source says Keytruda’s success came not only from being in the PD-1 class, but from clinical-development choices that broadened the product’s commercial lead.

In the episode, Keytruda’s scale becomes a strategic risk for Merck because patent expiration creates a revenue-replacement problem. That makes Chinese PD-1/VEGF data important even before mechanism and long-term survival evidence are fully settled.

Connections

• Merck / 默沙东 - company behind the product in the source.
• PD-1 Market Saturation and PD-1/VEGF Bispecific - market and mechanism context.
• Multinational Pharma Patent-Cliff Anxiety - strategic pressure created by future loss of exclusivity.